Back to results
US 2021/0196789 A1Published application
Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
AssigneeAmolyt Pharma
InventorsThomas DELALE, Stephane MILANO, Thierry ABRIBAT, David CLEMMONS
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.
Claims24
A method for modulating a metabolic disorder in a subject;
- the method comprising:
- administering to the subject a therapeutically effective amount of a peptide consisting of:
- i) a heparin binding domain (HBD) as set forth in SEQ ID NO:
- 1 or an analog thereof;
- ii) a fragment of the peptide as set forth in i);
- or iii) a pharmaceutically acceptable salt of any one of the peptide as set forth in i) and ii).
3 more elements
(canceled)
-26. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.